Ginkgo Bioworks Holdings Analyst Price Targets - Benzinga

SPY779.87+0.10%QQQ759.84+0.02%BTC/USD84,232.88−1.54%DIA514.66+0.02%GLD381.90−0.10%TLT77.20−0.10%

Ginkgo Bioworks Holdings Inc

DNANYSE

Trade with Public

Trade with Public

$12.41

-2.57-17.16%

Last update: Oct 6, 7:53 PM

$12.39

-2.59-17.29%

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Ginkgo Bioworks Holdings Analyst Price Targets - Benzinga

Ginkgo Bioworks Holdings Analyst Price Targets

Wall Street analyst price targets and consensus rating for Ginkgo Bioworks Holdings (DNA).

Price Target Range — 7 Quarters

Analyst Consensus — 5 Analysts

2Hold

3Sell

Consensus RatingSell# Analysts5Avg. Consensus PT$48Upside to Avg. PT+284.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 4, 2026	BTIG	Mark Massaro	Maintained	Sell	$5
Aug 7, 2026	TD Cowen	Brendan Smith	Downgrade	Buy→Hold	$12→$9
Mar 12, 2026	BTIG	Mark Massaro	PT Cut	Sell	$9→$5
Jan 8, 2026	TD Cowen	Brendan Smith	PT Cut	Buy	$14→$12
Aug 25, 2025	BTIG	Mark Massaro	PT Raise	Sell	$6→$9
Sep 20, 2024	TD Cowen	Brendan Smith	PT Raise	Buy	$3→$10
Aug 23, 2024	BTIG	Mark Massaro	Maintained	Sell	$0→$7
Jul 9, 2024	Goldman Sachs	Matthew Sykes	PT Cut	Sell	$1→$0
Jun 26, 2024	BTIG	Mark Massaro	PT Cut	Sell	$1→$0
May 15, 2024	BTIG	Mark Massaro	Downgrade	Neutral→Sell	—
May 15, 2024	Morgan Stanley	Tejas Savant	PT Cut	Equal-Weight	$2→$1
May 10, 2024	William Blair	Matt Larew	Downgrade	Market Perform→Underperform	—
Mar 1, 2024	TD Cowen	Steven Mah	PT Cut	Outperform	$7→$3
Jan 23, 2024	Goldman Sachs	Matthew Sykes	PT Cut	Sell	$1→$1
Jan 22, 2024	Goldman Sachs	Matthew Sykes	PT Cut	Sell	$1→$1
Nov 15, 2023	Raymond James	Rahul Sarugaser	Downgrade	Outperform→Market Perform	$3
Nov 14, 2023	Raymond James	Rahul Sarugaser	Downgrade	Outperform→Market Perform	$3
Nov 9, 2023	BTIG	Mark Massaro	Downgrade	Buy→Neutral	—

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BTIG Reiterates Sell on Ginkgo Bioworks Holdings, Maintains $5 Price Target

BTIG analyst Mark Massaro reiterates Ginkgo Bioworks Holdings (NYSE:DNA) with a Sell and maintains $5 price target.

Benzinga Newsdesk

PRO
TD Cowen Downgrades Ginkgo Bioworks Holdings to Hold, Lowers Price Target to $9

TD Cowen analyst Brendan Smith downgrades Ginkgo Bioworks Holdings (NYSE:DNA) from Buy to Hold and lowers the price target from $12 to $9.

Benzinga Newsdesk

PRO
BTIG Maintains Sell on Ginkgo Bioworks Holdings, Lowers Price Target to $5

BTIG analyst Mark Massaro maintains Ginkgo Bioworks Holdings (NYSE:DNA) with a Sell and lowers the price target from $9 to $5.

Benzinga Newsdesk

Ginkgo Bioworks Pivots To AI And Robotics After Rough Quarter

Ginkgo Bioworks stock drops after earnings miss, lower sales, and shift to autonomous labs and robotics focus.

Vandana Singh

PRO
TD Cowen Maintains Buy on Ginkgo Bioworks Holdings, Lowers Price Target to $12

TD Cowen analyst Brendan Smith maintains Ginkgo Bioworks Holdings (NYSE:DNA) with a Buy and lowers the price target from $14 to $12.

Benzinga Newsdesk

PRO
BTIG Maintains Sell on Ginkgo Bioworks Holdings, Raises Price Target to $9

BTIG analyst Mark Massaro maintains Ginkgo Bioworks Holdings (NYSE:DNA) with a Sell and raises the price target from $6 to $9.

Benzinga Newsdesk